Philadelphia chromosome-positive acute lymphoblastic leukemia

Yuichi Kodama, Hiroyuki Shimada

Research output: Chapter in Book/Report/Conference proceedingChapter


In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.

Original languageEnglish
Title of host publicationPediatric Acute Lymphoblastic Leukemia
PublisherSpringer Singapore
Number of pages7
ISBN (Electronic)9789811505485
ISBN (Print)9789811505478
Publication statusPublished - 2019 Jan 1


  • Bcr-abl1
  • Dasatinib
  • Philadelphia chromosome
  • Ponatinib
  • Tyrosine kinase inhibitor imatinib

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Philadelphia chromosome-positive acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this